A prospective randomized study comparing intramuscular progesterone and 17alpha-hydroxyprogesterone caproate in patients undergoing in vitro fertilization-embryo transfer cycles
Costabile L,Gerli S,Manna C,Rossetti D,Di Renzo GC,Unfer V
Published August 2001Fertility and Sterility, 76(2), 394-396
Costabile, L., Gerli, S., Manna, C., Rossetti, D., Di Renzo, G. C., & Unfer, V. (2001). A prospective randomized study comparing intramuscular progesterone and 17alpha-hydroxyprogesterone caproate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertility and Sterility, 76(2), 394-396. https://doi.org/10.1016/s0015-0282(01)01901-x
Costabile L, Gerli S, Manna C, Rossetti D, Di Renzo GC, Unfer V. A prospective randomized study comparing intramuscular progesterone and 17alpha-hydroxyprogesterone caproate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril. 2001;76(2):394-396. doi:10.1016/s0015-0282(01)01901-x
Costabile, Loredana, et al. "A prospective randomized study comparing intramuscular progesterone and 17alpha-hydroxyprogesterone caproate in patients undergoing in vitro fertilization-embryo transfer cycles." Fertility and Sterility, vol. 76, no. 2, 2001, pp. 394-396.
For EndNote, Zotero or Mendeley:
Open access
Free to read
No reuse license
Free to read at the publisher (reported by Unpaywall and OpenAlex, not verified by RRM Academy)
To compare the effectiveness of i.m. P and 17alpha-hydroxyprogesterone caproate (17-HPC) for luteal phase support, in patients undergoing IVF-ET cycles.
Design
Prospective, randomized study.
Setting
Patients undergoing IVF-ET in our Centers.
Patients
The inclusion criteria were the use of GnRH down-regulation and aged <40 years.
Interventions
A total of 300 cycles were randomly treated with either 17-HPC (341 mg every 3 days) or P (50 mg daily).
Main Outcome Measures
The outcomes of IVF in both study groups were evaluated for biochemical pregnancy, miscarriage, clinical pregnancy, and ongoing pregnancy.
Results
No difference was found in the main outcome parameters considered.
Conclusions
Although the results of the study encourage the use of 17-HPC for luteal phase support in patients undergoing IVF-ET program, more studies are necessary to support the hypothesis that it can replace i.m. P-in-oil.
